NexGen Biomedical, Inc. Provides New Insights Into Jett Travolta's Seizure Rel... ( SAN JOSE Calif. June 12 2012 /- ...)

NexGen Biomedical, Inc. Provides New Insights Into Jett Travolta's Seizure Related Death

Date:6/12/2012

SAN JOSE, Calif., June 12, 2012 /PRNewswire/ -- US patent 8,197,858 issued on June 12, 2012 discloses a previously unknown pathogenesis underlying seizures / epilepsy and migraines and provides novel treatment options for the 50 million seizure patients and 300 million migraine sufferers worldwide.

"We scientifically validated that triggers such as drops in estrogen or testosterone or increases in prostaglandin or Vitamin D synthesis all boost release of calcium ions from bone. We also validated that boosting extracellular calcium ion levels boosts seizure and migraine risk by 1) depolarizing nerve membranes, 2) increasing calcium channel mediated neurotransmitter release and 3) boosting muscle contractility," according to Mark Zamoyski, NexGen Biomedical, Inc.'s founder and the patent holder.

"Why 50 million people worldwide have low seizures thresholds is not clear, however, the new pathogenesis provides an insight into factors that would increase their risk of having a seizure," continued Mark Zamoyski. "We can begin to understand the perfect storm of risk factors that possibly contributed to 16 year old Jett Travolta's uncontrollable seizure while on a vacation in the Bahamas. Puberty brings nighttime testosterone surges, followed by daytime drops, which boost calcium ion release from bone. Sun exposure can boost Vitamin D synthesis to 25 times the RDA and sunburn boosts prostaglandin synthesis, both of which boost release of calcium from bone and hence boost seizure risk. And those are just some of the risk factors on the list."

"Previously unexplained migraine observations could now also be explained. As an example, one study found 45% of women with menstrual migraines had magnesium deficiency. The new pathogenesis explanation: It is known that estrogen levels drop precipitously at the start of menstruation. That in turn would result in a boost in extracellular
'/>"/>

SOURCE NexGen Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
2. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
3. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
4. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
7. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
8. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
9. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
10. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
11. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure

Post Your Comments:

(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...

(Date:6/19/2013)... -- Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...

(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...

[0] Drug Patent Watch [0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research

... , MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. (OTC ... the required three centers in its FDA clinical study of the ... , ProUroCare began the current study with the ... having more than 40 patients enrolled overall. Since beginning, five ...

... Aug. 10 Bionovo, Inc. (Nasdaq: BNVI ) today announced second quarter ... , Company Highlights , , , ... in 27 patients with metastatic breast cancer showed ... evidence of clinical activity, in a heavily pretreated ...

Cached Medicine Technology:ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 2 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 5 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 6 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 7 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 8

ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology Bionovo Announces Second Quarter 2009 Highlights and Financial Results

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...

(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...

(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...

(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...

(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...

Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2 Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3 Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2

[0] New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Long-term study reports deep brain stimulation effective for most common hereditary dystonia [0] States vary widely on success rates for minorities in drug treatment programs [0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center

... healthcare,provider and supplier organizations with its GHXcellence Awards for,achievements ... Friday, April 18, 2008 during a recognition ceremony in,Chicago ... largest healthcare,forum in the U.S. focused on both the ... theme of this year,s awards was improved utilization of ...

... Once locked in decades of isolation, Albania is seeing new ... demands for better and healthier lives. , People ... Institute of Public Health and Hygiene. They want better, more ... keep pace with those expectations, but there are problems. , ...

... Fla., April 23 LifeSync Corporation, a,wholly ... it has entered,into a non-exclusive sublicense with ... with the digital, wireless communication of,patient vital ... Wireless the right to utilize,LifeSync,s technologies in ...

... The Beryl Companies, the nation,s,leading healthcare call ... of operations. In this role she will oversee ... recruitment and,training of managerial staff. Butterfield brings nearly ... vendor management., "Lindy is a highly regarded ...

... for cancer patients , , WEDNESDAY, April 23 (HealthDay News) ... developing a simple way to measure oxygen levels in ... treatment is best for individual patients. , The ... for patients with cancer instead of treating people the ...

... quarter of ... per share, including net realized investment losses ... cash flow was $1.0 billion, or approximately 1.8 times net ... income, -- Full year 2008 net income is now expected to be in the range of $5.42 -, ...

GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance Albania: Rising expectations drive growing health care needs LifeSync Corporation Agrees to Sublicense Patent Portfolio to Triage Wireless New VP of Operations Enhances The Beryl Companies' Leadership Team Scan Detects Oxygen Levels in Tumors WellPoint Reports First Quarter 2008 Results

... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...

... a constant voltage power supply, the 105 is ... hilo range switch control the output, which is ... volts. One, two-position switch toggles the bright LED ... The 105 is equipped with an over current ...

... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...

MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...

Medicine Products:

Model 583 Gel Dryer (220-240 V)105 Low Voltage Power Supply High Voltage Programmable Power Supplies Midi Power Supply